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Abstract
Background: Mesenchymal stem cells (MSCs) are multipotent stem cells that can be isolated and expanded from
many tissues, and are being investigated for use in cell therapies. Though MSC therapies have demonstrated some
success, none have been FDA approved for clinical use. MSCs lose stemness ex vivo, decreasing therapeutic
potential, and face additional barriers in vivo, decreasing therapeutic efficacy. Culture optimization and genetic
modification of MSCs can overcome these barriers. Viral transduction is efficient, but limited by safety concerns
related to mutagenicity of integrating viral vectors and potential immunogenicity of viral antigens. Nonviral delivery
methods are safer, though limited by inefficiency and toxicity, and are flexible and scalable, making them attractive
for engineering MSC therapies.
Main text: Transfection method and nucleic acid determine efficiency and expression profile in transfection of
MSCs. Transfection methods include microinjection, electroporation, and nanocarrier delivery. Microinjection and
electroporation are efficient, but are limited by throughput and toxicity. In contrast, a variety of nanocarriers have
been demonstrated to transfer nucleic acids into cells, however nanocarrier delivery to MSCs has traditionally been
inefficient. To improve efficiency, plasmid sequences can be optimized by choice of promoter, inclusion of DNA
targeting sequences, and removal of bacterial elements. Instead of DNA, RNA can be delivered for rapid protein
expression or regulation of endogenous gene expression. Beyond choice of nanocarrier and nucleic acid,
transfection can be optimized by priming cells with media additives and cell culture surface modifications to
modulate barriers of transfection. Media additives known to enhance MSC transfection include glucocorticoids and
histone deacetylase inhibitors. Culture surface properties known to modulate MSC transfection include substrate
stiffness and specific protein coating. If nonviral gene delivery to MSCs can be sufficiently improved, MSC therapies
could be enhanced by transfection for guided differentiation and reprogramming, transplantation survival and
directed homing, and secretion of therapeutics. We discuss utilized delivery methods and nucleic acids, and
resulting efficiency and outcomes, in transfection of MSCs reported for such applications.
Conclusion: Recent developments in transfection methods, including nanocarrier and nucleic acid technologies,
combined with chemical and physical priming of MSCs, may sufficiently improve transfection efficiency, enabling
scalable genetic engineering of MSCs, potentially bringing effective MSC therapies to patients.
Keywords: Nonviral gene delivery, Transfection, Human mesenchymal stem cells, Cell therapy, Gene therapy,
Priming
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Background
Human mesenchymal stem cells (hMSCs)
Human mesenchymal stem cells (hMSCs) are multipotent
adult stem cells that can be easily isolated and expanded
from many tissues, including bone marrow (hBMSCs),
adipose (hAMSCs), and umbilical cord (hUCMSCs) [1].
hMSCs are tri-lineage multipotent in vitro (osteogenic,
adipogenic, and chondrogenic) [2], and home to sites of
inflammation in damaged tissues in vivo after transplant-
ation [3], where they can facilitate tissue repair through
differentiation for cell repopulation, and promote tissue
remodeling and modulation of the immune response
through secretion of growth factors, cytokines, and exo-
somes [4–12]. hMSCs are immune evasive [13], enabling
allogenic transplantation for cell therapies that make use
of the aforementioned properties. Additionally, MSCs can
be efficiently reprogrammed to generate induced pluripo-
tent stem cells (iPSCs) [14, 15]. Therefore, hMSCs are be-
ing widely investigated for use in cell therapies for
treatment of many diseases.
Over 200 hMSC cell therapy clinical trials have been
completed, and another 81 are currently active, accord-
ing to the US National Library of Medicine clinical trial
database. These clinical trials include therapies for treat-
ment of autoimmunity, graft versus host disease, ische-
mia, injury of central nervous system, and cancer [16].
Though clinical trials have demonstrated some measures
of success, no hMSC therapy has been approved by the
FDA for clinical use [17]. hMSC therapies have not re-
sulted in widespread success, in part due to challenges
associated with maintenance of stemness during expan-
sion ex vivo, resulting in progressive loss of self-renewal,
differentiation potential, and immunomodulatory cap-
acity that decrease hMSC therapeutic potential, as well
as additional challenges after delivery in vivo, including
transplantation survival and target engraftment [18–20].
To overcome the barriers that limit their performance in
therapies, and enhance their properties, hMSCs can be
modified by optimization of culture conditions and ex-
ogenous gene transfer, ex vivo. In expansion, stemness
maintenance can be enhanced by inclusion of media fac-
tors [21–24], and tuning of substrate properties or cul-
turing in 3-D [25–27], in order to suppress cell sene
scence. Loss of proliferative capacity, pluripotent gene
expression, and differentiation potential in MSCs are, in
part, due to senescence linked to low telomerase activity
[28, 29]. Through gene delivery, MSCs have been suc-
cessfully immortalized by induced expression of human
telomerase reverse transcriptase (hTERT), which signifi
cantly extends MSC expansion before replicative senes-
cence, while retaining expression of pluripotency genes,
immunosuppressive properties, and differentiation po-
tential [30, 31]. hMSCs can also be engineered ex vivo to
enhance therapeutic function in vivo, through induced
expression of pro-survival genes [32, 33], adhesion li-
gands targeting cell membrane receptors [34–36], line
age-specific genes for directed differentiation [37, 38], or
genes that encode for production and secretion of gro
wth factors [39, 40], cytokines [41, 42] and miRNA in
exosomes [43, 44]. Thus, many researchers are investi-
gating methods to efficiently transfer genes to MSCs.
Gene delivery to hMSCs
Gene delivery is the delivery of exogenous DNA or RNA
to cells to alter gene expression. The primary challenges
of gene delivery are efficiency and safety. Viral gene de-
livery systems use the naturally efficient mechanisms of
viruses to condense nucleic acids and mediate their in-
ternalization, trafficking, and expression within target
cells [45]. In general, these vehicles can be engineered by
addition of exogenous genes and removal of deleterious
viral genes to render replication-deficiency and decrease
pathogenicity [45]. Viral gene delivery, while highly effi-
cient, is limited by safety issues, including insertional
mutagenicity. Specifically, a clinical trial in which he
matopoietic stem cells (HSCs) were genetically modified
with retrovirus prior to transplantation resulted in four
patients developing leukemia due to insertional muta-
genic transformation [16]. Though MSCs have thus far
not been found tumorigenic in clinical trials [46, 47],
transduction with viral vectors could increase this risk.
Even with viral vectors that do not integrate, safety risks
of viral transduction in the manufacture of cell therapies
remain due to possible presentation [48] of viral antigens
on transduced cells that could potentially activate an im-
mune response in vivo following transplantation [49]. In
addition, viral systems are limited by relatively small
transgene cargo capacity, and difficulty in production
and scale-up [50]. Safety risks and manufacturing chal-
lenges motivate the development of methods for efficient
nonviral gene delivery to hMSCs. Nonviral gene delivery
methods are safer than viral methods, and are more scal-
able and flexible, but are less efficient and can be toxic,
especially in hMSCs. This review will discuss current
methods and materials for nonviral gene delivery to
MSCs, approaches that improve transfection efficiency
with MSC priming by media additives and culture sur-
face design, and potential clinical applications that utilize
nonviral gene delivery to MSCs.
Methods of nonviral nucleic acid delivery into
MSCs ex vivo
In nonviral gene transfer, delivery method and choice of
nucleic acid will determine transfection outcome. In this
section, we review microinjection, electroporation, and
nanocarriers as methods of nucleic acid delivery, high-
light DNA sequence considerations, compare delivery ef-
ficiencies of mRNA versus DNA cargoes, and discuss
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utility of oligonucleotide delivery, in the context of
MSCs.
MSC transfection via membrane disruption by
microinjection and electroporation
Effective strategies for nonviral transfection of MSCs ex
vivo typically employ disruption of cell membranes to
transfer nucleic acids into cells (e.g. microinjection, elec-
troporation) or packaging of nucleic acids with nanocar-
rier materials that facilitate cellular internalization thr
ough endocytosis [51]. For both membrane disruption-
and nanocarrier-mediated delivery, intracellular barriers
remain following nucleic acid delivery to the cytoplasm,
including lysosomal and nuclease degradation, and for
plasmid DNA (pDNA), cytoplasmic transport to and im-
port through the nuclear membrane into the nucleus
[51]. Nuclear localization of plasmid is eased in prolifer-
ative cell types due to dissolution of the nuclear mem-
brane during mitosis; conversely, nuclear localization of
plasmids is challenging in primary cell types such as
MSCs, which proliferate slowly and are hard-to-transfect
[52]. Thus, microinjection of plasmids into MSCs is effi-
cient when delivered directly into the nucleus, demon-
strated in single or few MSCs with nanoneedles 200–
275 nm in diameter, with 75% viability retained after in-
jection and 65–75% reporter transgene expression effi-
ciency (i.e. percentage of cells expressing transgene) [53,
54]. However, microinjection is impractical for transfect-
ing large numbers of cells.
Electroporation is a higher throughput alternative to
microinjection that applies transient electric fields to cell
populations, typically in suspension, inducing pores in
cell membranes that allow entry of nucleic acids into the
cytoplasm [55], though induced charge association be-
tween nucleic acids and cell membranes followed by
endocytosis has been demonstrated as an alternative me
chanism [56]. Electroporation is economical (not neces-
sarily requiring additional reagents beyond suspension
buffer) and is widely used for DNA and RNA transfec-
tion of MSCs with high efficiency, as described below
[57], though as with microinjection, nuclear localization
is a primary barrier for plasmid delivery via electropor-
ation [58]. A commercial electroporation system known
as Nucleofector (Lonza, Germany) employs cell-type
specific electric field pulse parameters and proprietary
suspension solution formulations to drive plasmid DNA
transfer directly to the nucleus, a method termed
nucleofection [59]. Nucleofection of MSCs has been
demonstrated to increase transfection efficiency of plas-
mid delivery relative to conventional electroporation
[60], with approximately 68% transfection efficiency in
MSCs electroporated in Nucleofector buffer suspension
and subsequently re-plated [61], however cell viability
after nucleofection was reported as 54%.
While effective at transfection, as reported above, elec-
troporation is limited by cytotoxicity, which is attributed
to effects of the pulsed electric fields on biomolecules,
including electroconformation change of lipid mem-
branes, proteins, and DNA, and oxidative damage from
generated reactive oxygen species [55]. Additional mech-
anisms of electroporation cytotoxicity include Joule heat-
ing, pH change, and metal ions electrolytically shed
from aluminum, copper, or stainless-steel electrodes into
the electroporation buffer solution [55]. The Neon
(Thermo Fisher Scientific, USA) micro-electroporation
system uses long, narrow, low volume capillaries, as op-
posed to traditional electroporation cuvettes, decreasing
changes in pH, and allowing for economical use of small
gold electrodes that are more electrolytically inert [62].
Using micro-electroporation (notably with an earlier ver-
sion of the Neon system), plasmid delivery to hUCMSCs
achieved approximately 80% transfection efficiency and
80% viability [63]. However, while electroporation meth
ods are efficient, current laboratory-scale electroporation
systems are low-throughput. Clinical application of elec-
troporation to MSCs will require significant scale-up
that maintains high transfection efficiency and achieves
high viability, which remains a challenge. Nanocarriers
described below are a potentially more scalable approach
for nonviral gene delivery to MSCs.
MSC transfection via nanocarrier materials
The primary alternative to electroporation for nucleic
acid transfer into MSCs ex vivo is transfection with
nanocarriers, materials that electrostatically condense or
encapsulate nucleic acids into nanoparticles or aggregate
complexes that favorably associate with cell membranes
through charge interactions or surface receptor binding,
and are subsequently internalized via macropinocytosis,
clathrin-mediated endocytosis, or caveolae-mediated en
docytosis, depending primarily on nanoparticle size and
charge [64]. Generally, size and charge of nanoparticles
can be tuned by varying the ratio of nucleic acid to
nanocarrier formulation. A wide variety of carriers have
been demonstrated to facilitate transfection of MSCs, in-
cluding polymers, lipids, polysaccharides, peptides, and
inorganic materials [65].
Cationic lipids are commonly used for transfection of
MSCs, for example, Hoare et al. [66] transfected hBM
SCs with pDNA encoding for enhanced green fluores-
cent protein (EGFP) complexed with the commercially
available cationic lipid transfection reagent, Lipofecta-
mine (LF) 2000. Transfection efficiency increased from
20 to 40% and viability decreased from 80 to 50%, as the
lipid/pDNA (v/w) ratio increased from 5 to 20, respect-
ively. A newer version of LF, LF-LTX, was used by Kelly
et al. [67] and achieved 2–6% transfection efficiency after
48 h in hBMSCs with significantly decreased metabolic
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activity compared to untransfected hBMSCs, while the
latest LF iteration, LF3000, achieves up to 26% transfec-
tion efficiency in hBMSCs, according to de Carvalho et
al., though viability was not reported [68].
For comparison of several other types of nanocarriers,
Gonzalez-Fernandez et al. [69] tested biocompatible min
eral nano-hydroxyapatite (nHA), the ubiquitous cationic
polymer transfection reagent 25 kDa branched polyethy-
lenimine (bPEI), and repeating arginine–alanine-leuci-
ne-alanine (RALA) amphipathic peptide for porcine
BMSC transfection with pDNA encoding GFP. All three
nanocarriers exhibited transfection efficiency between 15
and 20% and metabolic activity was not significantly
decreased after 3 days, with the exception of PEI, which
exhibited a 30% decrease in metabolic activity relative to
untransfected control.
While nanocarriers, in general, have thus far not
achieved transfection efficiency in MSCs that competes
with electroporation or viral vectors while maintaining
high viability, through flexibility of design and chemical
modification, continuous improvements to nanocarriers
are being developed. For example, nanocarriers can be
functionalized with ligands to facilitate cellular uptake of
nanoparticles. To improve nanoparticle uptake by MSCs,
Saraf et al. [70] functionalized bPEI with hyaluronic acid,
which binds to MSC surface receptor CD44, and this
modified bPei was used to deliver pDNA encoding EGFP
to hMSCs, resulting in 3-fold higher transfection effi-
ciency than unfunctionalized bPEI transfection. In a
similar approach, Santos et al. [71] functionalized a com-
monly used gene delivery dendrimer, poly(amidoamine)
(PAMAM), with proprietary peptides that were previ-
ously reported to target MSCs with high affinity. The
targeting peptides significantly increased plasmid uptake
by hMSCs and increased luciferase transgene expression
10-fold after 48 h, without significantly decreasing cell
viability, relative to unmodified PAMAM. To promote
transport to nuclei, nuclear localization sequences (
NLS), which are found on transcription factors and fa-
cilitate their transport into nuclei [72], have been incor-
porated into nanocarriers. For example, Hoare et al. [66]
incorporated NLS peptides into LF2000-pDNA com-
plexes, and demonstrated hBMSC luciferase transgene
expression was increased about 10-fold (varying between
different NLS), relative to hBMSC transgene expression
mediated by lipoplexes without an NLS.
The highest transfection efficiency reported in the litera-
ture for transfection of MSCs via nanocarriers has been
achieved by biocompatible and degradable poly(β-ami-
no-esters) (PBAE). In Mangraviti et al. [73], a library of
PBAEs was screened in high-throughput to determine
which polymers could mediate high transfection without
decreased viability in hAMSCs. The highest-performing
PBAE, PBAE536e, had a molecular weight of 8.5 kDa, and
when mixed with DNA at a 40:1 ratio by mass, achieved
75% transfection efficiency and 71% viability. These PBAE
nanocarriers achieve transfection efficiency similar to, and
viability higher than, optimized electroporation methods,
and are therefore promising candidates for scaling nonvi-
ral gene delivery to MSCs for clinical applications.
While these studies demonstrate that nanocarriers
have the potential to be achieve high transfection effi-
ciency, it should be noted that vast differences in trans-
fection outcomes are reported, presumably due to varia
bility in species, tissue source, passage, and donor of the
MSCs. MSCs are universally characterized by expression
of specific surface markers (CD73+, CD90+, CD105+),
but expression of pluripotency transcription factors and
surface markers varies between tissue sources, and do-
nors [74], resulting in differences in proliferative capacity
[75], differentiation potential [75], and immunomodula-
tory potency [76], and presumably transfection effi-
ciency. For example, we showed in our most recent
work [77] that LF3000 mediated transgene expression
between hBMSCs and hAMSCs, and between donors,
varied by up to 10-fold. Similarly, Madeira et al. [78] re-
ported LF2000 mediated transfection efficiency of
hBMSCs at passage one to vary between 5 and 20% be-
tween donors, and to decrease with increasing passage
number. Thus donor variability may explain the differ-
ences in reported transfection efficiency by different
groups using the same MSC nonviral delivery methods,
and direct comparisons of different methods on the
same donor(s) are required to truly determine the high-
est performing nanocarriers. Furthermore, for a nanocar-
rier to be considered for clinical applications, it must be
demonstrated to work on many different donors, which
may also require engineering of the nucleic acid cargo,
as described next.
Engineering plasmids and minicircles for nuclear delivery
in MSC transfection
In addition to engineering nanocarriers, optimization
and incorporation of plasmid sequence elements can be
used to enhance nuclear delivery and expression of
genes. Plasmid sequence elements (e.g. promoters [79,
80], enhancers, and CpG sites [81, 82]) can determine
the rate of transgene transcription in a cell-dependent
manner [83], therefore design of plasmid sequences can
dramatically affect transgene expression. While many
plasmid elements have been studied and optimized in
cell lines, these variables still need to be studied in the
context of hMSCs. As a first step towards plasmid op
timization in hMSCS, we have demonstrated that
LF3000 transfection of hBMSCs and hAMSCs with
pDNA encoding for a fusion protein of EGFP and lucif-
erase, driven by cytomegalovirus (CMV) promoter, re-
sulted in 10-fold higher transgene expression than
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transfection with plasmids containing elongation factor
1 α (EF1α) or rous sarcoma virus (RSV) promoters [77],
even though the EF1α promoter has been previously
shown to outperform the CMV promoter in rat MSCs
[84–86]. Comparing these results suggests hMSC physi-
ology may differ significantly from MSCs obtained from
other species, and therefore, findings related to transfec-
tion efficiency in non-human MSCs must be thoroughly
validated in hMSCs.
Aside from promoter selection, another consideration
of pDNA design are sequences that may be required for
efficient nuclear transport. DNA sequences have been
identified that are bound by transcription factors (that
present NLS), facilitating import into nuclei, termed
DNA targeting sequences (DTS) [87–95]. To investigate
the role of DTS-facilitated plasmid transport in hBMSCs
and hAMSCs transfected with LF3000, our group has
found that removal of the SV40 DTS from pDNA re-
sulted in up to 50% less transgene expression [77] com-
pared to without SV40 DTS removal. Therefore, DTS
must be incorporated into pDNA design for efficient
MSC transfection.
While plasmid sequence elements can be designed to
enhance transfection efficiency in MSCs, plasmid back-
bone elements like replication of origin and antibiotic
resistance genes can trigger intracellular inflammation
and transgene silencing [96], potentially limiting trans-
fection efficiency. Therefore, recent transfection studies
have investigated minicircle DNA (mcDNA), nucleic
acids that are derived from pDNA by recombination
that removes bacterial sequences. Narsinh et al. [97]
generated mcDNA from parental pDNA by placing a
eukaryotic expression cassette containing the desired
genes for transfection (without bacterial elements) be-
tween sites for ϕC31 integrase recombination. Indu-
cible ϕC31 integrase activity cleaved out the bacterial
backbone leaving the remaining eukaryotic cassette as
the mcDNA. The mcDNA contained iPSC reprogram-
ming factors OCT4, SOX2, NANOG, and LIN-28, that
induced pluripotency in transfected hAMSCs. Electro-
porated mcDNA increased transfection efficiency 6-fold
in transfected hAMSCs compared to pDNA, and after
12 days, transgene mRNA expression was 5-fold higher
(resulting in a reprogramming efficiency of about
0.005%). The increase in transfection efficiency and
duration of transfection suggest that mcDNA is a
promising nonviral vector for MSC gene delivery. How-
ever, the additional recombination and purification re-
quired to produce mcDNA currently limits widespread
use. Therefore, development of optimized pDNA trans-
fection methods for MSCs is still necessary, as well as
well as RNA transfection methods that do not require
nuclear transport and transcription for expression, as
described next.
Cytoplasmic delivery of mRNA and oligonucleotides in
MSC transfection
While there are benefits to plasmid delivery, such as
relatively simple manufacture and chemical stability,
hMSCs can be more efficiently transfected with mRNAs
than with pDNA, presumably by eliminating the need
for nuclear transport and transcription of the delivered
pDNA. Thus researchers are working to optimize mRNA
delivery to MSCs. Lipofection of hMSCs with LF-RNAi
MAX complexed with mRNA resulted in 60% transfec-
tion efficiency [98], which is significantly higher than
typical lipofection efficiencies using pDNA [66–68].
However, while mRNA may mediate higher transfection
efficiency, the temporal expression profile of mRNA is
shorter in duration than pDNA. For example, nucleofec-
tion of MSCs with mRNA has been reported to result in
significantly higher early transfection efficiency than
with pDNA (80% versus 40%, at day 1, respectively),
while pDNA transfection reaches higher efficiency at
later time points (25% versus 45%, at day 8) [99]. The
shorter duration, but more efficient expression of trans-
gene by mRNA transfection may require repeated dos-
ing, yet may be advantageous in some applications,
suggesting that careful selection of nucleic acid cargo is
a key transfection design parameter in MSCs.
In addition to mRNA, oligonucleotides can also be
transfected for modulation of endogenous gene expres-
sion. Small interfering RNA (siRNA) and microRNA
(miRNA) are both short RNA oligonucleotides that can
inhibit expression of complementary RNAs through
binding and inducing cleavage by the RNA-induced si-
lencing complex (RISC) or by inhibiting translation
[100]. Like DNA and mRNA, siRNA and miRNA can be
delivered via nanocarriers. For example, Benoit et al.
[101] developed a di-block co-polymer (pDMAEMA-b-
p(DMAEMA-co-PAA-co-BMA)) consisting of an siRNA
complexation block (pDMAEMA) and an endosomal es-
cape block (tercopolymer of PAA, BMA, and DMA
EMA) for efficient siRNA delivery to hBMSCs. Perform-
ance of the di-block co-polymer was compared to the
commercial transfection reagent, DharmaFECT, by
quantifying hBMSC siRNA uptake, cell viability, and tar-
get gene silencing against the housekeeping gene, glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH). After
24 h, 96% of hBMSCs were siRNA-positive when trans-
fected with the co-polymer, while DharmaFECT trans-
fected at 64% efficiency. There was no significant
decrease in viability with co-polymer transfection, while
DharmaFECT decreased viability to about 50%. Relative
to untreated hBMSCs, the co-polymer decreased
GAPDH expression by up to 92%, while DharmaFECT
decreased expression by 75% at equivalent siRNA dose.
The differences in knockdown and viability in hBMSCs
between co-polymer and DharmaFECT mediated siRNA
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delivery, suggests that choice of nanocarrier is important
in oligonucleotide delivery to MSCs. In summary of
DNA and RNA delivery, protein expression, and en-
dogenous gene regulation can be achieved with various
temporal expression profiles and transfection efficien-
cies, depending on choice and design of nucleic acid. To
complement DNA and RNA delivery, co-delivery of pro-
teins can also be used, as discussed in the next section.
Co-delivery of proteins and nucleic acids in MSCs ex vivo
Though MSCs can be effectively engineered with nucleic
acids, there are applications for which co-delivery of
both proteins and nucleic acids may be desirable. For ex-
ample, towards development of a nanocarrier for
co-delivery of an osteogenic transcription factor and
pDNA encoding for bone morphogenic protein BMP-2,
Park et al. [102] transfected hBMSCs with PEI-coated
poly(lactic-co-glycolic acid) (PLGA) nanoparticles, that
were loaded with red fluorescent protein (RFP), and
coated with pDNA encoding for GFP-tagged BMP2. At
24 h after delivery, 25% of hBMSCs expressed GFP-
tagged BMP2, while 33% contained RFP, indicating suc-
cessful delivery of both protein and pDNA. Co-delivery
of proteins and nucleic acids also enables implementa-
tion of CRISPR/Cas9 systems for targeted gene modifi-
cation. Xu et al. [103] used electroporation to co-deliver
a Cas9/guide RNA ribonucleoprotein (Cas9/gRNA RNP)
with gRNA sequence targeting the beta2-microglobulin
(B2M) gene, and a single stranded oligodeoxyribonucleo-
tide (ssODN), to hAMSCs. Co-delivery resulted in B2M
expression knock out, from 96% B2M+ in untransfected
hAMSCs to 19% B2M+ in transfected hAMSCs, demon-
strating successful co-delivery and function of the Cas9/
gRNA RNP and ssODN system in hAMSCs. These stud-
ies demonstrate successful nonviral co-delivery of pro-
teins and nucleic acids to MSCs for applications that
may require the presence of protein prior to, or simul-
taneously with, nucleic acid expression, expanding the
possible methods by which MSC phenotype and geno-
type can be modulated. However, it is clear that with
current delivery methods, transfection efficiency is a pri-
mary limitation for applications that seek to make use of
nonviral gene transfer to MSCs, therefore innovative ap-
proaches for improving nonviral gene delivery are being
investigated, as described next.
Recent approaches to improve nonviral gene
delivery to MSCs
Though nucleic acids, carriers, and delivery methods can
be optimized for enhanced transfection efficiency in
MSCs, culture media additives and culture surface prop-
erties can also be optimized to ‘prime’ cells for transfec-
tion success, i.e. modulate the cell response to gene
transfer in order to enhance transfection efficiency.
Next, we present techniques which utilize chemical
priming agents (media additives) known to influence
transfection efficiency in MSCs, and also briefly discuss
the mechanisms by which these additives modulate
transfection barriers. Additionally, we present evidence
that demonstrates cell culture surface stiffness and pro-
tein coatings can influence transfection efficiency in
MSCs through physical priming, suggesting further
design parameters that must be considered when devel-
oping efficient techniques for nucleic acid delivery to
these adult stem cells.
Priming with media additives
Glucocorticoids mitigate transfection toxicity to enhance
transfection efficiency
After initial identification in a high-throughput screen of
over 700 clinically approved compounds to discover
priming agents that can enhance transfection in cell
lines [104], we have shown that glucocorticoids (Gc) can
dramatically enhance transfection in MSCs ex vivo [67].
In Kelly et al. [67], we demonstrated in hBMSCs derived
from multiple donors, that 100 nM of the Gc dexa-
methasone (DEX) delivered 0–30min prior to transfec-
tion with three different types of pDNA complexes
(formed with either 25 kDa bPEI, LF-2000, or LF-LTX)
increased luciferase transgene expression relative to un-
primed transfected hBMSCs (3-, 5-, and 10-fold, respect-
ively). In addition to increasing transgene expression,
DEX priming of LF-LTX transfection increased hBMSC
transfection efficiency about 3-fold, relative to unprimed
transfected hBMSCs. We further demonstrated that this
DEX-priming effect required binding of the glucocortic-
oid receptor (GR), by observing that DEX-priming was
abrogated when GR binding was inhibited with the
GR-antagonist RU486. DEX-primed transfection-increa
ses correlated with rescue of decreased metabolic activity
induced by transfection, suggesting that hBMSC trans-
fection toxicity can be ameliorated by DEX priming,
through modulation of gene expression by the transcrip-
tional activity of DEX-activated GR [67]. In addition,
DEX-primed hMSCs retained their differentiation cap-
acity after transfection, compared to unprimed hMSCs,
which exhibited decreased adipogenic and osteogenic
differentiation potential after transfection. In Hamann et
al. [77], we next investigated the specific mechanisms by
which DEX priming enhances transfection of both
hBMSCs and hAMSCs, with studies suggesting DEX
priming may affect protein synthesis and rescue of
transfection-induced apoptosis. In summary, DEX-pri
ming mechanisms suggest that mitigating transfection-
induced toxicity can dramatically improve transfection
efficiency in MSCs. Therefore, future studies will investi-
gate new candidate priming compounds known to act
on relevant stress pathways.
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Microtubule acetylation and stabilization enhance
transfection efficiency
Another transfection priming approach is to improve
nuclear localization of pDNA by stabilizing microtu-
bules. Inhibition of cytoplasmic histone deacetylases
confers microtubule stability through enrichment of
acetyl modifications that increase microtubule flexibility
[105]. Dean et al. [106] demonstrated, through histone
deacetylase 6 (HDAC6) knockdown, that increased acetyl-
ation and improved stability of microtubules results in
more efficient pDNA nuclear localization, suggesting
HDAC6 inhibition is a potent transfection priming mech-
anism. Transfection priming with HDAC6 inhibitors has
been applied to MSCs to improve transfection. For ex-
ample, Ho et al. [107] explored priming of transfection to
hBMSCs, using 25 kDa linear PEI- primed with the
HDAC6 inhibitor, Tubastatin A (10 μM), in combination
with DOPE/CHEM, a lipid mixture that facilitates poly-
plex endosomal escape prior to lysosomal degradation.
Relative to unprimed transfected hBMSCs, priming with
Tubastatin A and DOPE/CHEM dramatically increased
hBMSC transfection efficiency, from 30 to 70%, demon-
strating HDAC6 inhibition as a component of an efficient
MSC transfection priming strategy. In a similar approach,
Dhaliwal et al. [108] transfected mBMSCs with pDNA en-
coding for luciferase complexed with 25 kDa linear PEI in
both 2-D on tissue culture polystyrene (TCPS) and in 3-D
culture within RGD (Arg-Gly-Asp) -conjugated hyaluronic
acid hydrogels, primed with paclitaxel, which limits
microtubule depolymerization. Relative to unprimed
transfected mBMSCs, mBMSCs primed with 10 μM pacli-
taxel 2 h prior to delivery of polyplexes exhibited 8-fold
and 35-fold increases in luciferase transgene expression
without decreasing viability, in 2-D and 3-D, respectively.
These studies reveal the possibility that cytoskeletal
modulation can influence transfection efficiency, suggest-
ing further investigations into the interplay between cyto-
skeletal dynamics and transfection success are needed for
improved nucleic acid delivery to MSCs.
Priming by design of culture surfaces
In addition to microtubule stability, cytoskeletal network
tension also plays key roles in rate limiting steps of non-
viral gene delivery, through RhoGTPase pathways that
modulate the organization of actin stress fibers, which
are involved in nanoparticle internalization and endocy-
tic trafficking. [109–114] Actin stress fibers maintain
cytoskeletal tension in cell spreading, which is modu-
lated by surface stiffness, surface chemistry, and protein
adhesion ligand presentation, and has been demon-
strated to correlate with enhanced transfection [115–
119]. Therefore, design of these surface properties may
be a viable strategy for MSC transfection priming.
In a relatively stiff modulus regime (10 to 670 kPa),
Chu et al. [119] transfected mouse D1 BMSCs on
fibronectin-coated poly(ethylene glycol) diacrylate hydro
gels, using 25 kDa linear PEI complexed with pDNA en-
coding for bone morphogenic protein BMP-2. BMP-2
transgene expression was significantly increased on 670
kPa versus 10 kPa hydrogels (2-fold increase), corre-
sponding with an observed 6-fold significant increase of
polyplex internalization. In comparing soft versus stiff
substrates, Modaresi et al. [120] tested delivery of pDNA
encoding for vascular endothelial growth factor (VEGF)
complexed with LF2000, to hAMSCs cultured on 0.5 or
32 kPa poly(dimethylsiloxane) PDMS surfaces coated
with 1% (w/v) gelatin. VEGF transgene expression was
significantly higher (4.5-fold) in hAMSCs cultured on
32 kPa versus 0.5 kPa PDMS, which correlated to a
2.5-fold significant increase in lipoplex internalization,
which was shown to be correlated with increased caveo
lae-mediated endocytosis. Alternatively, within a soft
stiffness regime (0.1 to 1.7 kPa), Gojgini et al. [118] dem-
onstrated that mouse BMSCs encapsulated in 3-D hya-
luronic acid hydrogels were more spread, and
demonstrated increased transfection, at softer stiffnesses.
pDNA encoding luciferase was complexed with 25 kDa
linear PEI and delivered to BMSCs through incorpor-
ation into the hydrogels. As hydrogel stiffness was in-
creased from 0.1 to 1.7 kPa, luciferase transgene expre
ssion decreased 5-fold, correlating with increased BMSC
spreading and metabolic activity in the softer hydrogels.
The authors suggested that decreased migration and
spreading due to smaller pore size in the stiffer hydro-
gels as a potential mechanism that decreased transfec-
tion. The results of these studies suggest that trans
fection efficiency depends on stiffness, and potentially
the dimensionality of the culture (i.e. 2-D versus 3-D),
and positive or negative correlation of cell spreading and
transfection with surface stiffness that depends on stiff-
ness regime [116, 118, 119].
In addition to stiffness tuning, MSC transfection can
also be primed by surface or scaffold presentation of
proteins. Dhaliwal et al. [121] demonstrated D1 mouse
BMSC transfection to vary on TCPS coated with various
proteins (vitronectin, collagen I, collagen IV, laminin, fi-
bronectin, and ECMg, a mixture of extracellular matrix
(ECM) -derived proteins and proteoglycans). In BMSCs
transfected with pDNA encoding for luciferase com-
plexed with 25 kDa linear PEI, transgene expression was
increased on coatings of fibronectin, collagen IV, and
ECMg (up to 6-, 15-, and 7-fold), decreased on collagen
I (up to 10-fold), and not significantly different on lam-
inin or vitronectin, relative to uncoated TCPS. The ob-
served modulation of transgene expression was attri
buted to coating-dependent differences in cell prolifera-
tion, spreading, integrin expression, and polyplex interna
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lization. Therefore, priming of transfection by protein
coatings on surfaces may be an approach to improve ex
vivo gene delivery to MSCs.
These chemical and physical priming studies suggest
that in addition to improvements to nanocarrier design
and optimization of electroporation and nucleic acid fea-
tures, future strategies to optimize nonviral gene delivery
to MSCs for clinical applications may utilize the strat-
egies of priming cells both with media additives and cul-
ture surface design. With methods and protocols that
enable routine transfection in MSCs with high efficiency,
clinical applications will be possible, as discussed below.
Applications of nonviral gene delivery to MSCs
With current nanocarrier and electroporation technol-
ogy, progress has been made in the development of gen-
etically modified MSC-based cell therapies. We present
a broad survey of literature reporting nonviral gene de-
livery to MSCs, reviewing applications in which MSC
transfection conferred additional functionality, illustrat-
ing the promise of MSCs for gene therapies that are not
limited by the safety concerns associated with viral vec-
tors. Applications of MSC transfection discussed below
include tissue engineering, differentiation, reprogram-
ming, promoting survival post-transplantation, directing
tissue homing, secretion of therapeutic biomolecules,
and cancer therapies.
Nonviral gene delivery to MSCs for tissue engineering,
differentiation, and reprogramming
MSCs have great potential in tissue engineering, particu-
larly for bone and cartilage engineering. A common en-
gineering strategy is to seed MSCs within 3-D scaffolds
and provide chemical or physical cues for differentiation
into desired tissues. Tissue formation can be enhanced
with genetically guided differentiation of MSCs, medi-
ated by nonviral gene delivery [122]. Nonviral gene de-
livery can also facilitate MSC reprogramming beyond
mesodermal lineage. Below, we present research in
which MSCs were transfected to engineer bone, cartil-
age, insulin-secreting cells, vascular tissue, and iPSCs.
Gene delivery for MSC differentiation in bone and cartilage
tissue engineering
A promising method to deliver recombinant proteins for
tissue regeneration, [123, 124] is the use of MSCs, trans-
fected to transiently secrete physiological levels of growth
factors to direct specific differentiation and remodeling in
target tissue. In an example of bone regeneration, Park et
al. [102] co-delivered BMP-2 pDNA with runt-related
transcription factor 2 (RUNX2) protein with PEI-coated
PLGA nanoparticles to induce osteogenesis of hBMSCs.
The combination of BMP-2 expression and transcriptional
regulation by RUNX2 was expected to improve osteogenic
differentiation over BMP-2 expression or RUNX2 activity
alone. In vitro, hBMSCs transfected with both BMP-2
pDNA and RUNX2 protein displayed 20-fold higher
osteogenesis-related gene expression than hBMSCs trans-
fected with only BMP-2 pDNA or RUNX2 protein. This
trend followed in vivo, resulting in more robust bone re-
generation 28 days after subcutaneous injection into nude
mice [102]. Similar approaches using MSCs are under
study for engineering of articular cartilage to treat defects.
For example, in a scaffold-mediated nanocarrier delivery
approach, He et al. [125] transfected rat MSCs by seeding
cells within gelatin scaffolds containing pDNA encoding
transforming growth factor beta-1 (TGFβ-1) complexed
with pullulan-spermine, for cartilage regeneration in
full-thickness rat cartilage defects. MSCs within scaffolds
that delivered TGFβ-1 pDNA were expected to enhance
chondrogenesis compared to MSCs within scaffolds that
did not deliver TGFβ-1 pDNA. Indeed, proteoglycan and
glycosaminoglycan (GAG) histological analysis revealed
that scaffolds with transfected MSCs expressing TGFβ-1
induced more cartilage repair than scaffolds with untrans-
fected MSCs [125]. Using transfection prior to scaffold
seeding, alternative to the previous scaffold-mediated
transfection approach, Bucher et al. directed differenti-
ation of hBMSCs into a phenotype resembling interverte-
bral disc (IVD) cells by electroporation with pDNA
encoding for growth and differentiation factor 5 (GDF5)
[126], prior to seeding within alginate hydrogels. Trans-
fected hBMSCs in alginate beads expressed GDF5 for up
to 21 days and upregulated chondrogenic markers aggre-
can and SOX9, and the discogenic marker KRT19 [126].
When GDF5-expressing hMSCs were injected into an in
vitro bovine IVD degeneration model, IVD cartilage
regeneration was enhanced, as evidenced by 5-fold in-
crease of GAG to DNA ratio, compared to injection of
untransfected hMSCs. These studies demonstrate that
MSC differentiation can be successfully guided by nonviral
delivery of genes encoding for growth factors.
An alternative to transfection with growth factor genes
to direct differentiation is transfection with genes encod-
ing transcription factors that regulate differentiation.
Park et al. [127] induced chondrogenesis in hMSCs by
delivering pDNA encoding SOX5, SOX6, and SOX9,
using PEI on PLGA nanoparticles. As evidenced by
staining of collagen II, aggrecan, and cartilage oligomeric
matrix protein, hMSCs transfected with the three SOX
factors exhibited robust chondrogenesis, while untrans-
fected hMSCs and hMSCs transfected with only individ-
ual SOX genes remained undifferentiated [127]. Comple
mentary to regulation of differentiation with transgenic
growth factors or transcription factors, oligonucleotide
delivery can also direct MSC differentiation through
post-transcriptional gene regulation. To guide chondro-
genic differentiation by decreasing translation of osteo
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genic transcription factor RUNX2, Xu et al. [128] deliv-
ered complexes of RGD-modified-β-cyclodextrin with
RUNX2 siRNA to hMSCs, resulting in significant knock-
down of RUNX2 and downregulation of hypertrophy
osteogenic marker collagen X in vitro. In subcutaneous
hyaluronic acid hydrogels in mice, transfected hMSCs
enhanced chondrogenic differentiation, as evidenced by
decreased calcification and increased staining of collagen
II, GAGs, and proteoglycans. Together, these studies
demonstrate successful histologically-verified recapitula-
tion of bone and cartilage generated by MSCs enhanced
with nonviral gene delivery in vitro and in animal mo
dels and motivates further development of regenerative
treatments of bone and cartilage defects utilizing engi-
neered MSCs.
Gene delivery for MSC Transdifferentiation
In addition to enhancing tissue formation through meso-
dermal lineage differentiation, like bone and cartilage,
nonviral gene delivery can facilitate MSC differentiation
to cell types outside of mesodermal lineage, for example
β-cell or endothelial cell transdifferentiation, with uses
in treatment of diabetes and vascular tissue engineering,
respectively. Through nucleofection of mRNA encoding
for PDX-1 prior to chemical induction of β-cell differen-
tiation, Van Pham et al. [129] doubled the efficiency of
hUCMSC β-cell differentiation, in comparison to hUC
MSCs differentiated by chemical induction alone, achie
ving up to 8% insulin-positive β-cell phenotype. The
enrichment of β-cell differentiation by PDX-1 transfec-
tion was functionally verified by two-fold increases in
production of insulin and C-peptide in response to glu-
cose [129]. Towards differentiation of MSCs into endo-
thelial cells (ECs), Park et al. [130] induced endothelial
differentiation by delivering PLGA nanoparticles loaded
with angiogenesis-related peptide (apelin), coated with
PEI and pDNA encoding for vascular endothelial growth
factor (VEGF) to hMSCs. Transfected hMSCs expressed
angiogenic factors, formed tight tubular vessel structures
in vitro, and rehabilitated ischemic limbs in mice in vivo
by facilitating neovascularization. The successful demon-
stration of β-cell and EC phenotypes from MSC transdif-
ferentiation utilizing nonviral delivery suggests MSCs
can be a cell source for engineering of tissues outside
mesodermal lineage, expanding the potential range of
MSC clinical applications. Future challenges will include
increasing transfection and differentiation efficiency, and
demonstration of functional transdifferentiated pheno-
types in vivo.
Gene delivery for reprogramming of MSCs into iPSCs
In addition to being a promising cell type for applica-
tions requiring mesodermal- or trans-differentiation,
hMSCs are also an attractive source for iPSCs. MSCs
have been shown to be induced to pluripotency by inte-
grating viral vectors at 0.2% efficiency, which is 2-fold
higher than fibroblast reprogramming efficiency [131].
To bypass the safety drawbacks associated with viral
gene delivery discussed earlier, Narsinh et al. [15] repro-
grammed hAMSCs into iPSCs by nucleofecting mcDNA
encoding for reprogramming factors, Lin28, Nanog,
Sox2, and Oct4. Transfection of hAMSCs with mcDNA
was 4-fold more efficient than with pDNA, and provided
higher transgene expression over a longer period of time.
Reprogramming efficiency was only about 0.005% in
hAMSCs, which was 10-fold more efficient than repro-
gramming of differentiated neonatal fibroblasts using the
same methods [132]. Alternative to potentially muta-
genic viral vectors and inefficient nonviral episomal vec-
tors, reprogramming genes can be integrated at specific
sites in the MSC genome, and subsequently removed
after iPSC generation, utilizing sequence-specific recom-
binases. Jia et al. [14] reprogrammed mAMSCs to iPSCs
by nucleofecting with pDNA encoding for the repro-
gramming factors Oct4, Sox2, Klf4, and cMyc, and con-
taining recognition sites for ϕC31 integrase, flanked by
loxP sites to allow removal after reprogramming. ϕC31
integrase was expressed from a separate pDNA to inte-
grate the reprogramming cassette into mAMSC ge-
nomes. Excision of the reprogramming cassette by Cre
recombinase was 50% efficient [14], and reprogramming
was achieved at 0.03% efficiency, which is more efficient
in comparison to the study above, which achieved repro-
gramming efficiency of 0.005% using mcDNA [15],
though animal source and reprogramming genes dif-
fered. These studies demonstrate that MSCs can be suc-
cessfully reprogrammed into iPSCs via nonviral gene
delivery. However nonviral iPSC reprogramming from
MSCs remains inefficient, presumably, in part, due to
transfection inefficiency. Therefore, methods that im-
prove nonviral gene delivery will enable efficient MSC
into iPSC reprogramming via transfection, for clinical
-scale applications requiring pluripotent stem cells.
Nonviral nucleic acid delivery to MSCs for cell therapies
As natural effectors of tissue regeneration that can be
accessibly harvested from adult donors, MSCs have
been extensively investigated for cell-based therapies
in animal models and human trials, for applications
ranging from repair of cartilage [133], bone [134],
and myocardium [135, 136], to immunosuppression of
graft versus host disease (GvHD) and restoration of
bone marrow stroma in HSC transplantation [137–
139]. Requirements of MSC therapies include cell
survival after transplantation, target tissue engraft-
ment, and controlled secretion of therapeutic biomol-
ecules at sufficient levels. As discussed below, ectopic
exogenous gene expression has been utilized to
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enhance and endow hMSCs with these properties to-
wards improving MSC therapeutic efficacy.
Promoting transplantation survival
For cell therapies, MSCs must migrate to, and confer
their therapeutic effects in, tissue microenvironments of
ischemia, inflammation, and oxidative stress, which can
result in poor MSC survival. For example, only 7% of
MSCs transplanted into infarcted animal myocardium
survive, after a few days [140]. For this reason, re-
searchers have investigated ways to enhance survival of
transplanted MSCs. One strategy to promote survival is
nonviral gene delivery of pro-survival or anti-apoptotic
factors to MSCs. For example, Song et al. [141] lipo-
fected rat BMSCs with complexes of LF-PLUS and
pDNA encoding for the MSC mitogen, fibroblast growth
factor-2 (FGF-2). Compared to untransfected BMSCs,
FGF-2 transfection increased BMSC viability 3-fold after
24 h of in vitro hypoxia and serum starvation conditions
that simulate transplantation stress, expressing 2-fold
higher levels of anti-apoptotic gene Bcl2. When BMSCs
were injected into infarcted rat myocardium, FGF-2
transfected BMSCs significantly increased neovasculari-
zation after 4 weeks, compared to untransfected BMSCs,
presumably, in part, due to FGF-2 induced increase in
survival and proliferation after transplantation. Alterna-
tively, MSC survivability under hypoxic conditions could
possibly be improved through enzymatic mitigation of
heme toxicity. Tang et al. [32] endowed mBMSCs with
the ability to inducibly express heme oxygenase-1
(HO-1) in ischemic environments by delivering pDNA
encoding for HO-1 complexed with PEI Transferinfec-
tion reagent (Bender MedSystems, USA) to mBMSCs.
The pDNA was designed with promoter regions driving
the HO-1 gene that are recognized by transcription
factors GAL4/p65. GAL4/p65, fused with an oxygen
degradation domain, was constitutively expressed from
the same plasmid, endowing hypoxia-induced HO-1
transcriptional activation to transfected mBMSCS.
Transplanted into ischemic mouse myocardiums, trans-
fected mBMSCs exhibited increased survival about
10-fold over control mBMSCs for 7 days, resulting in
less myocardial fibrosis and improved hemodynamic
heart function [32]. Finally, in an approach alternative to
ectopic expression of growth factors or cytoprotective
proteins, miRNA delivery can regulate gene expression
pathways that promote survival. For example, Xu et al.
[142] endowed rat BMSCs with improved ability to sur-
vive H2O2 treatment in vitro by lipofecting BMSCs with
miR-20 and LF2000, which increased activity of super-
oxide dismutase (SOD) and c-Met to reduce oxidative
stress and subsequent BMSC apoptosis 2-fold compared
to untransfected MSCs, suggesting miR-20 transfection
could increase survival and therapeutic effects of MSCs
in vivo when exposed to oxidative environments. Over-
all, through nonviral delivery of miRNA known to regu-
late oxidative and inflammatory stress responses, along
with genes encoding for growth factors and cytoprotec-
tive enzymes, MSC transplantation survival can poten-
tially be maximized to enable effective MSC therapies.
Directing tissue homing
In addition to transplantation survival, MSCs must reach
target tissues in sufficient numbers to realize therapeutic
effects. Several groups have utilized nonviral gene deliv-
ery to direct MSCs to specific tissues or to enhance the
innate tissue homing ability of MSCs, which could im-
prove their therapeutic potential and reduce the MSC
dose required for therapeutic effect. Levy et al. [98] en-
hanced the ability of hBMSCs to selectively invade in-
flamed tissue by lipofection with LF-RNAiMAX and
mRNA encoding for the adhesion ligands PSGL-1 and
SLeX, achieving 60% transfection efficiency of both pro-
teins. PSGL-1 and SLeX facilitate cell tethering and roll-
ing on inflamed vascular endothelium. Consequently,
30% more systemically administered transfected hBM
SCs localized to inflamed mouse ears than untransfected
hBMSCs [98]. In a chemotactic approach, Mun et al.
[97] enhanced mBMSC active migration to injury sites
by electroporating mcDNA encoding for chemokine re-
ceptor type 4 (CXCR4) into mBMSCs, which facilitates
migration towards stromal cell-derived factor 1 (SDF1).
Transfected mBMSCs maintained transgene expression
for up to 7 days [97]. When systemically injected into
mice, CXCR4-transfected mBMSCs efficiently homed to
full-thickness skin wounds, whereas unmodified mB
MSCs accumulated in lungs and were cleared. The di-
rected homing of CXCR4-expressing mBMSCs towards
injury resulted in a significant decrease in wound closure
time [97]. These studies demonstrate great potential of
transfection of MSCs with genes that direct tissue hom-
ing to enhance their therapeutic effect and decrease ne-
cessary dosing.
Engineering the MSC Secretome
In addition to engineering MSCs for enhanced survival
and tissue-targeting, nonviral gene delivery can enable
MSCs to become drug delivery vehicles, secreting trans-
genic biomolecules that have therapeutic effects, includ-
ing angiogenic factors, immunomodulatory cytokines,
anti-tumorigenic factors, and engineered exosomes,
which we discuss below.
Growth factors
VEGF is a growth factor that induces endothelial tube
formation in angiogenesis. Deveza et al. [143] engineered
hAMSCs by delivering pDNA encoding for VEGF com-
plexed with PBAE, resulting in 3-fold more VEGF
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secretion than unmodified hAMSCs, for up to 8 days.
VEGF secreted into media by transfected hAMSCs in-
duced significantly increased angiogenesis by human
vein endothelial cells (HUVECs) in vitro relative to
media from untransfected hAMSCs. When these VEGF-
overexpressing hAMSCs were applied to mouse excision
skin wounds, angiogenesis was significantly increased
and wound closure time was decreased by 2 days, rela-
tive to untransfected hAMSCs [144]. In contrast to tran-
sient overexpression of VEGF by MSCs, Cho et al. [145]
used a genome engineering approach to achieve sus-
tained expression of VEGF in hUCMSCs. hUCMSCs
were transfected with pDNA encoding for an inducible
TALEN system that integrated a VEGF sequence into a
safe harbor site within the genome. Engineered hUC
MSCs secreted 50-fold more VEGF than control
hUCMSCs in vitro at 2 weeks after integration of the
gene. When engineered hUCMSCs were transplanted
into infarcted rat myocardium, heart function was sig-
nificantly improved by all metrics. Infarct size and fibro-
sis were also decreased by about 2-fold after 3 weeks,
relative to transplant of control hUCMSCs [145]. Thus,
transient and sustained VEGF secretion from MSCs has
been demonstrated to be effective for angiogenic appli-
cations. MSCs can also be transfected to secrete growth
factors relevant to other applications. For example, in a
neurodegenerative disease application, Dey et al. [146]
engineered mBMSCs to secrete about 7-fold more brain
derived neurotrophic factor (BDNF) than control
mBMSCs by transfection of PEI complexed with pDNA
encoding for BDNF. When transplanted into brains of a
Huntington’s disease (HD) mouse model, engineered
mBMSCs significantly rescued loss of neurons and im-
proved motor function, compared to transplantation of
untransfected mBMSCs [146]. To summarize, nonviral
gene delivery has been used to achieve both transient
and sustained overexpression of growth factors. In ani-
mal models, transfected MSCs have produced growth
factors that improved wound healing, and enhanced
myocardial (VEGF) and neural (BDNF) regeneration,
suggesting growth factor secretion from engineered
MSCs as a viable strategy for cell therapies.
Immunomodulation
MSCs can also be transfected to secrete immunomodu-
latory factors. Specifically, several studies have investi-
gated MSC secretion of cytokines that reduce inflam
mation. For example, Levy et al. [98] lipofected hBMSCs
with LF-RNAiMAX complexed with mRNA encoding
for anti-inflammatory cytokine interleukein-10 (IL-10) to
induce IL-10 secretion. Transfected hBMSCs secreted
over 10-fold more IL-10 than untransfected hBMSCs,
for up to 4 days. Co-culture of transfected hBMSCs with
CD4 T cells resulted in about a 2-fold reduction in T cell
proliferation in vitro, compared to co-culture with
untransfected hBMSCs. When hBMSCs overexpressing
IL-10 were administered to mice with inflamed ears, in-
flamed ear thickness was decreased by about 2-fold, rela-
tive to hBMSCs not overexpressing IL-10, indicating
enhanced inflammation suppression [98]. Similarly, to
reduce injury in a lung inflammation mouse model,
Mei et al. [147] electroporated mouse MSCs with
pDNA encoding for angiopoietin1 (ANGPT1), a protein
that protects against vascular inflammation and pro-
motes EC survival. Transfected MSCs secreted
ANGPT1 for 5 days in vitro, and when injected into
mouse jugular veins after lipopolysaccharide (LPS)-in-
duced lung injury, transfected MSCs mediated attenu-
ation of inflammation, as evidenced by reduction in
neutrophil invasion and inflammatory cytokines, and de
creased lung permeability, as evidenced by reductions
in IgG and albumin, all compared to injection of
untransfected MSCs.
Immunomodulatory factors can also be transfected in
MSCs for stable expression. For example, by transposon-
mediated integration, Petrakis et al. [148] nucleofected
hAMSCs with a pDNA transposon encoding interferon
beta-1 (IFNB1) and a separate plasmid encoding the
SB100x transposase, resulting in efficient transposition
that generated stable expression of IFNB1, demonstrated
by 70% of transfected hAMSCs secreting IFNB1 4 weeks
later. Though INFB1 is known to upregulate peripheral
blood mononuclear cell (PBMC) secretion of immuno-
suppressive cytokines such as IL-10 and IL-4 [149],
PBMC stimulation by the engineered hAMSCs was not
tested. However, these studies do demonstrate MSCs
can be transfected for transient or stable expression of
immunomodulatory factors. Therefore, MSCs can poten-
tially be engineered to decrease inflammation as a facet
of MSC-based cell therapies.
Cancer therapeutics
Many studies have genetically modified MSCs, which
naturally home to tumors [150], to secrete anti-tumo
rigenic factors, or to express suicide enzymes that cleave
pro-drugs, inducing cytotoxicity in tumors. For secretion
of an anti-tumorigenic factor, Mangraviti et al. [73] engi-
neered hAMSCs to treat glioblastoma by transfecting
with PBAE complexed with pDNA encoding for secreted
BMP-4, which significantly suppressed growth of brain
tumor initiating cells (BTIC) in vitro. In addition to
achieving 75% transfection efficiency and high viability,
AMSCs transfected with PBAEs displayed significantly
higher motility and invasion in vitro than AMSCs trans-
duced with lentivirus [73]. When engineered hAMSCs
were administered intranasally to mice with glioblast-
oma, survival was prolonged, relative to mice that
received control hAMSCs [73]. Another commonly
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investigated anti-tumorigenic factor for delivery to tu-
mors by MSCs is tumor necrosis factor related apoptosi-
s-inducing ligand (TRAIL). In a specific example, Jiang
et al. [151] transfected hAMSCs with PBAE complexed
with TRAIL-expressing pDNA, achieving 68% transfec-
tion efficiency and about 90% viability, which was
5.5-fold more efficient that LF2000. Transfected
hAMSCs were injected into brains of patient-derived
tumor xenograft (PDTX) glioblastoma NCr nude mouse
model, and migrated to tumor margins. Compared to
untransfected hAMSCs, TRAIL-expressing hAMSCs de-
creased tumor size 2.5-fold and increased survival time.
Alternatively to anti-tumorigenic factor secretion, MSCs
have also been transfected for suicide gene therapy. For
example, Zhang et al. transfected rat BMSCs with
spermine-pullulan complexed with pDNA encoding thy-
midine kinase (TK). BMSCs were injected into a mouse
B16F10 pulmonary melanoma metastasis model and mi-
grated to tumor nodules. Upon systemic treatment with
pro-drug ganciclovir, TK secreted from transfected
BMSCs cleaved ganciclovir to its cytotoxic form within
tumors, reducing the number of metastatic lung nodules
by 70%, and decreasing lung weight by 30%. In a differ-
ent novel suicide gene approach that increases radioio-
dine uptake in tumors, Schug et al. [152] stably
transfected hBMSCs with sleeping beauty transposon
encoding for sodium iodide symporter (NIS) driven by a
TGFβ-1-responsive promoter, to induce expression of
NIS when hBMSCs are within tumor stroma that se-
cretes TGFβ-1. Engineered hBMSCs sequestered iodine
when stimulated with TGFβ-1 in vitro, and were there-
fore tested further in vivo, injected systemically into
mouse liver cancer models. Mice that received radioio-
dide therapy, exhibited delayed tumor growth and ex-
tended survival, relative to mice that did not receive
radioiodide therapy [152], suggesting successful
tumor-localized, hBMSCs sequestration of radioiodide.
To summarize, MSCs can be engineered to secrete
anti-tumorigenic factors and to facilitate suicide gene
therapy using nonviral gene delivery, with demonstrated
effectiveness in animal cancer models that may translate
to effective human cancer therapies.
Engineering exosome production, targeting, and cargoes
Intercellular transfer of exosomes, which contain organ-
elles, proteins, and RNAs, is thought to be a mechanism
by which MSC therapeutic effects are conferred. Isolated
MSC exosomes have been utilized to treat pre-clinical
models of cardiovascular, neurological, musculoskeletal,
and immune system diseases [4]. However, the thera-
peutic effects of MSC exosomes can be enhanced by
nonviral gene delivery. For example, to promote survival
and function of transplanted islet cells in a diabetic
mouse model, Wen et al. [153] transfected hMSCs with
pDNA encoding for siRNA against genes involved in
pancreatic islet graft failure, Fas and miR-375. In
co-culture with human islet cells in vitro, hMSCs trans-
ferred transgenic siRNA to islet cells via exosomes, pro-
moting islet cell survival and rescuing islet cell function
decreased by inflammatory cytokines. These transfected
hMSCs were then co-transplanted with human pancre-
atic islets into diabetic mice with humanized immune
systems, which resulted in increased islet survival and
function, and suppressed islet immune rejection in com-
parison to islets co-transplanted with untransfected
hMSCs [153]. In addition to passive loading of hMSC
exosomes with overexpressed oligonucleotides, nonviral
gene delivery to increase exosome production and ac-
tively load exosomes with transgenic mRNA has also
been demonstrated in hMSCs by Kojima et al. [154]. To
increase exosome production, hMSCs were electropo-
rated with pDNA encoding for three proteins involved
in exosome biogenesis, producing 10-fold more exo-
somes than untransfected hMSCs, and similarly, through
transgenic expression of CD63 fusion proteins with tar-
geting ligands or mRNA-binding petides, hMSC exo-
somes were engineered to present targeting ligands and
load mRNA cargoes [154]. Thus, with efficient nonviral
gene delivery, hMSC exosomes can be produced in large
quantities, passively or actively loaded with RNA, and
targeted with tissue- or cell type-specific ligands, as de-
livery vehicles for gene therapies.
Conclusions
MSCs are a promising cell type for allogenic transplant-
ation cell therapies because of their ease of isolation and
expansion, multipotent differentiation capacity, and regen-
erative and immunomodulatory properties. Yet, challenges
remain before widespread clinical application of MSC
therapies can be realized. Engineering of MSCs through
gene delivery approaches could help to overcome barriers
to translation of MSC therapies and endow cells with en-
hanced therapeutic efficacy. A primary concern in the
manufacture of genetically modified MSCs is the safety of
viral vectors, motivating the development of nonviral vec-
tors. Recent developments in nonviral delivery methods,
including nanocarrier technology and plasmid design, in
combination with chemical and physical priming of cells
during culture ex vivo, may allow for improved nonviral
transfection efficiency, enabling scalable translation of
genetically engineered MSC therapies for a variety of ap-
plications, including guided differentiation and repro-
gramming, transplantation survival and directed homing,
and secretion of therapeutics, potentially bringing effective
regenerative medicine to patients.
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disease; H2O2: Hydrogen peroxide; hAMSC: Human adipose derived MSC;
hBMSC: Human bone marrow derived MSC; HD: Huntington’s disease;
HDAC6: Histone deacetylase 6; hMSC: Human MSC; HO-1: Heme oxygenase-
1; HSC: Hematopoietic stem cell; hUMSC: Human umbilical cord MSC;
HUVEC: Human vein endothelial cells; IFNB1: interferon beta 1;
IgG: immunoglobulin G; IL-10: interleukin-10; IL-4: interleukin-4; iPSC: induced
pluripotent stem cell; IVD: intervertebral disc; kDa: kilodalton; kPa: kilopascals;
LF: Lipofectamine; LF2000: Lipofectamine 2000; LF3000: Lipofectamine 3000;
LF-LTX: Lipofectamine LTX; LF-PLUS: Lipofectamine-Plus; LF-
RNAiMAX: Lipofectamine RNAiMAX; LPS: Lipopolysaccharide; mAMSC: mouse
AMSC; mBMSC: mouse BMSCs; mcDNA: minicircle DNA; miRNA: micro RNA;
mRNA: messenger RNA; MSC: Mesenchymal stem cell; nHA: nano-
hydroxyapatite; NIS: sodium iodide symporter; NLS: Nuclear localization
sequence; nm: nanometer; nM: nanomolar; PAA: Propylacrylic acid;
PAMAM: Poly(amidoamine); PBAE: Poly(β-amino-esters); PBMC: Peripheral
blood mononuclear cells; pDMAEMA: poly(dimethylaminoethyl
methacrylate); PDMS: Polydimethylsiloxane; pDNA: plasmid DNA;
PDTX: Patient-derived tumor xenograft; PEI: Polyethylenimine; pH: decimal
co-logarithm of hydrogen; PLGA: Poly(lactic-co-glycolic acid);
RALA: Repeating arginine-alanine-leucine-alanine; RFP: Red fluorescent
protein; RGD: Arg-Gly-Asp; RISC: RNA-induced silencing complex;
RNA: Ribonucleic acid; RSV: Rous sarcoma virus; RUNX2: Runt-related
transcription factor 2; SDF1: Stromal cell-derived factor 1; siRNA: small
interfering RNA; SOD: Superoxide dismutase; ssODN: Single stranded
oligodeoxynucleotide; SV40: Simian virus 40; TALEN: Transcription activator-
like effector nuclease; TCPS: Tissue culture polystyrene; TGFβ-1: Transforming
growth factor β-1; TK: Thymidine kinase; TRAIL: Tumor necrosis factor related
apoptosis inducing ligand; VEGF: Vascular endothelial growth factor; w/
v: weight/volume
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